Disappointed with the results. Shouldn't have ignored some red flags (creating a new subsidiary with a different focus just a month before data, not presenting data (getting accepted) at a major conference like ESMO or SITC, to name a few). Lost trust in Heat's management after this, so I'm not sure how much to take this seriously - they have also mentioned in today's PR that they will be presenting on 12/6 a presentation at IASLC titled "Viagenpumatucel-L Bolsters Response to Nivolumab...in NSCLC." Any thoughts Dew?
Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.